🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. Unesbulin

    PTC THERAPEUTICS, INC.

    Leiomyosarcoma

    phase 3 small molecule terminated

    2 trials

  2. Upadacitinib

    AbbVie

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  3. Upadacitinib (ABT-494)

    AbbVie

    Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  4. Upadacitinib, Placebo for upadacitinib tablet, Upadacitinib, Upadacitinib

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  5. Ustekinumab Dose Based on BSA and Body Weight

    Janssen Cilag International NV

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial

  6. VK2735

    Viking Therapeutics

    Weight Loss

    phase 3 small molecule active

    4 trials

  7. VP4896

    Voyager Therapeutics

    Alzheimer's Disease

    phase 3 small molecule completed

    1 trial

  8. Vatiquinone

    PTC THERAPEUTICS, INC.

    Mitochondrial Diseases

    phase 3 small molecule terminated

    1 trial

  9. Vatiquinone

    PTC Therapeutics International Limited

    Friedreich Ataxia

    phase 3 small molecule active

    1 trial

  10. Vatiquinone

    PTC THERAPEUTICS, INC.

    Friedreich Ataxia

    phase 3 small molecule active

    3 trials

  11. Vatiquinone

    PTC THERAPEUTICS, INC.

    Inherited Mitochondrial Disease

    phase 3 small molecule completed

    1 trial

  12. Vatiquinone

    PTC THERAPEUTICS, INC.

    Friedreich ataxia

    phase 3 small molecule active

    1 trial

  13. Vedolizumab

    Takeda

    Ulcerative Colitis

    phase 3 small molecule completed

    9 trials

  14. Vedolizumab

    Takeda

    Colitis, Ulcerative

    phase 3 small molecule completed

    5 trials

  15. Vedolizumab 300 mg IV

    Takeda

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial

  16. Vedolizumab IV

    Takeda

    Ulcerative Colitis

    phase 3 small molecule active

    4 trials

  17. Vedolizumab IV

    Takeda

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  18. Vedolizumab SC

    Takeda

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial

  19. Vedolizumab SC

    Takeda

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  20. Vehicle to Mecloderm Ointment, LOTRICOMB® Salbe, 0,64 mg/g + 10 mg/g, Salbe, Mecloderm Ointment

    Alphapharm Pty Ltd

    moderate to severely inflamed candidiasis of the skin

    phase 3 small molecule active

    1 trial

  21. Veltassa 8.4 g powder for oral suspension, Placebo

    Istituto Gentili S.r.l.

    End Stage Kidney Disease on chronic dialysis therapy

    phase 3 small molecule active

    1 trial

  22. Venclexta, Venclyxto, Levact 2,5 mg/ml Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Venclexta, Venclyxto, Fludarabinphosphat "Ebewe", koncentrat til injektions-/infusionsvæske, opløsning, Venclexta, Venclyxto, Fludarabin Ebewe 25 mg/ml injektio-/infuusiokonsentraatti, liuosta varten, Fludarabin Sandoz 25 mg/ml injekčný alebo infúzny koncentrát, MabThera 500 mg concentrate for solution for infusion, Levact 2,5 mg/ml poudre pour solution à diluer pour perfusion, Bendamustin cell pharm® 2,5

    Hoffmann-La Roche

    Chronic Lymphocytic Leukemia (CLL)

    phase 3 small molecule active

    1 trial

  23. Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, BGB-11417, MabThera 100 mg concentrate for solution for infusion, BGB-11417, BGB-11417, Gazyvaro 1,000 mg concentrate for solution for infusion., BGB-11417, MabThera 500 mg concentrate for solution for infusion, Venclyxto 50 mg film-coated tablets

    BEONE MEDICINES AUS PTY LTD

    Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  24. Venclyxto 100 mg film-coated tablets, Levact 2,5 mg/ml poudre pour solution à diluer pour perfusion, BGB-16673, BGB-16673, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, MabThera 500 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion, Zydelig 150 mg film-coated tablets, Zydelig 100 mg film-coated tablets

    BEONE MEDICINES AUS PTY LTD

    Chronic lymphotic leukemia and Small Lymphocytic lymphoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources